One‐stop clinic for ketamine‐associated uropathy: report on service delivery model, patients' characteristics and non‐invasive investigations at baseline by a cross‐sectional study in a prospective cohort of 318 teenagers and young adults
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: To describe a service delivery model and report the baseline characteristics of patients investigated by a non‐invasive approach for ketamine‐associated uropathy. Patients and Methods: This was a cross‐sectional study in a prospective cohort of patients who attended their first visit and underwent non‐invasive investigations at a dedicated centre to treat ketamine‐associated uropathy in H ong K ong from D ecember 2011 to J uly 2013. Data on demographics, illicit ketamine use, symptoms scores and voiding function parameters at baseline were prospectively collected. Differences between active abusers and ex‐abusers, and risk factors for the most symptomatic group were investigated by univariate and multivariate analysis. Results: In all, 318 patients completed the non‐invasive assessment at their first visit and were eligible for inclusion. In all, 174 were female and the mean ( sd ) age of the entire cohort was 24.4 (3.1) years. Patients had used ketamine for a mean ( sd ) period of 81 (36) months. The mean ( sd ) ketamine use per week was 18.5 (15.8) g. In all, 214 patients were active abusers while 104 were ex‐abusers but had persistent lower urinary tract symptoms. The mean ( sd ) voided volume, bladder capacity, and bladder emptying efficiency were 111.5 (110) mL, 152.5 (126) mL and 73.3 (26.9)%, respectively. The ex‐abusers had a lower symptom score (19.3 vs 24.1; P < 0.001), a larger voided volume (126 vs 85 mL; P < 0.001), and a larger bladder capacity (204.8 vs 126.7 mL; P < 0.001) compared with active abusers. Multivariate analysis found female gender was associated with a higher symptom score (odds ratio [ OR ] 2.39; 95% confidence interval [ CI ] 1.35–4.23; P = 0.003) and a smaller voided volume ( OR 1.9; 95% CI 1.1–3.3; P = 0.02). Ketamine taken (g/week) was another risk factor for a higher symptom score ( OR 1.03; 95% CI 1.01–1.05; P = 0.002). Status of ex‐abuser was the only protective factor associated with fewer symptoms, larger voided volume and bladder capacity. Conclusions: An effective service model for recruiting patients with ketamine‐associated uropathy is possible. With such a service model as a platform, further prospective studies are warranted to investigate the appropriate choice of treatment for this new clinical entity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berry, S. H., Elliott, M. N., Suttorp, M., Bogart, L. M., Stoto, M. A., Eggers, P., Nyberg, L., & Clemens, J. Q. (2011) · Journal of Urology · doi:10.1016/j.juro.2011.03.132 · Cited by 595
Cited by
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Esketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
Possible pathophysiology of ketamine‐related cystitis and associated treatment strategies
Jhang, J., Hsu, Y., & Kuo, H. (2015) · International Journal of Urology · doi:10.1111/iju.12841 · Cited by 106
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Clinical staging of ketamine-associated urinary dysfunction: a strategy for assessment and treatment
Wu, P., Wang, Q., Huang, Z., Wang, J., Wu, Q., & Lin, T. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1759-9 · Cited by 28
Metadata
- Authors
- Tam, Y., Ng, C., Pang, K. K., Yee, C., Chu, W. C., Leung, V. Y., Wong, G. L., Wong, V. W., Chan, H. L., & Lai, P. B.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2014-10-22
- Volume
- 114
- Issue
- 5
- Pages
- 754-760
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1665395590
- Cited by
- 54
- References
- 1
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.